

Christian Sutter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9120998/publications.pdf>

Version: 2024-02-01

46
papers

4,234
citations

236925
25
h-index

276875
41
g-index

46
all docs

46
docs citations

46
times ranked

8364
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	21.4	513
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
3	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
6	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
7	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
8	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
9	Gene panel testing of 5589 <i>BRCA1/2</i> negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancer Medicine</i> , 2018, 7, 1349-1358.	2.8	126
10	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
11	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
12	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	3.5	105
13	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	2.5	102
14	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	2.9	91
15	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	1.6	90
16	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
18	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78

#	ARTICLE	IF	CITATIONS
19	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001974.	1.2	54
20	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
21	The association between breast cancer and S100P methylation in peripheral blood by multicenter caseâ€“control studies. <i>Carcinogenesis</i> , 2017, 38, 312-320.	2.8	41
22	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
23	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
24	DNA methylation array analysis identifies breast cancer associated <i>RPTOR</i> , <i>MGRN1</i> and <i>RAPSN</i> hypomethylation in peripheral blood DNA. <i>Oncotarget</i> , 2016, 7, 64191-64202.	1.8	33
25	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>BRCA2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
26	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
27	Performance of Breast Cancer Polygenic Risk Scores in 760 Female <i>CHEK2</i> Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 893-899.	6.3	21
28	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	4.1	20
29	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
30	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
31	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
32	Periungual fibroma (Koenen tumors) as isolated sign of tuberous sclerosis complex with tuberous sclerosis complex 1 germline mutation. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 159-161.	1.2	13
33	Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3292.	3.7	11
34	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
35	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. <i>BMC Cancer</i> , 2019, 19, 787.	2.6	10
36	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making â€“ A Selected Case Series. <i>Klinische Padiatrie</i> , 2018, 230, 305-313.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Germline testing for homologous recombination repair genesâ€”opportunities and challenges. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 332-343.	2.8	7
38	Breast cancer characteristics and surgery among women with Liâ€”Fraumeni syndrome in Germanyâ€”A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 7747-7758.	2.8	7
39	The <i>GPRC5A</i> frameshift variant c.183del is not associated with increased breast cancer risk in <i>BRCA1</i> mutation carriers. <i>International Journal of Cancer</i> , 2019, 144, 1761-1763.	5.1	2
40	<i>BRCA1/2</i> mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1090-1090.	1.6	2
41	Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. <i>Cancers</i> , 2022, 14, 3363.	3.7	2
42	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	1.2	1
43	DNA methylation array analyses to identify HYAL2 methylation in peripheral blood as a marker for the detection of early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 26-26.	1.6	0
44	NGS-based multi-gene panel analysis in <i>BRCA1/2</i>-negative breast and ovarian cancer families.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1526-1526.	1.6	0
45	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. <i>Neuro-Oncology</i> , 2022, 24, i154-i154.	1.2	0
46	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, i76-i76.	1.2	0